Harmse D P
Am Heart J. 1991 Jan;121(1 Pt 2):341-5. doi: 10.1016/0002-8703(91)90869-j.
This study was designed to investigate the efficacy and toleration of once-daily doxazosin in the treatment of essential hypertension (sitting diastolic blood pressure 95 to 115 mm Hg) in a general medical practice. Fifty-three patients with mild or moderate essential hypertension entered a study of 14 weeks' duration. This consisted of a baseline run-in period of 2 weeks, a dose-adjustment phase with doxazosin (8 weeks), and a maintenance phase of 4 weeks. Doxazosin was initiated at 1 mg/day, and every 2 weeks the dose was doubled unless blood pressure was normalized (sitting diastolic blood pressure less than or equal to 90 mm Hg with greater than or equal to 5 mm Hg reduction from baseline) or significant side effects emerged. The maximum daily dose administered was 8 mg. Doxazosin produced a significant (p less than 0.05) final mean change in sitting blood pressure of -17.4/-12.2 mm Hg at a final mean daily dose of 4.1 mg. Heart rate was not significantly altered. A nonsignificant decrease in total cholesterol concentration (-2.66%, p = 0.06) and triglycerides (-8.80%, p = 0.09) was also observed. The effect of doxazosin on blood pressure and serum cholesterol resulted in a significant (p less than 0.001) reduction of 19% in calculated risk of coronary heart disease. The investigators' assessment of patient toleration of doxazosin was excellent or good in 86.8% of patients.
本研究旨在调查在普通医疗实践中，每日一次服用多沙唑嗪治疗原发性高血压（坐位舒张压95至115毫米汞柱）的疗效和耐受性。53例轻度或中度原发性高血压患者进入了一项为期14周的研究。该研究包括2周的基线导入期、多沙唑嗪剂量调整阶段（8周）和4周的维持阶段。多沙唑嗪起始剂量为1毫克/天，每2周剂量加倍，除非血压恢复正常（坐位舒张压小于或等于90毫米汞柱且较基线降低大于或等于5毫米汞柱）或出现明显副作用。最大日剂量为8毫克。在最终平均日剂量为4.1毫克时，多沙唑嗪使坐位血压产生了显著（p小于0.05）的最终平均变化，为-17.4/-12.2毫米汞柱。心率无显著改变。还观察到总胆固醇浓度（-2.66%，p = 0.06）和甘油三酯（-8.80%，p = 0.09）有不显著的降低。多沙唑嗪对血压和血清胆固醇的影响使冠心病计算风险显著（p小于0.001）降低了19%。研究者对患者多沙唑嗪耐受性的评估显示，86.8%的患者耐受性为优或良。
